Lowenthal Richard E's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Aug 15, 2024
- Accession no.
- 0001415889-24-021362
- Filed
- Aug 15, 2024
- Trade date
- Aug 13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.25M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lowenthal Richard ECIK 0001378550 | Director, Officer (PRESIDENT AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2024 | Common Stock | SSaleDisposed | −14,599 | $11.78 | −$171,976.22 | 1,481,895 | Indirect | |
| Aug 13, 2024 | Common Stock | SSaleDisposed | −35,401 | $12.76 | −$451,716.76 | 1,446,494 | Indirect | |
| Aug 13, 2024 | Common Stock | SSaleDisposed | −14,637 | $11.77 | −$172,277.49 | 1,583,862 | Indirect | |
| Aug 13, 2024 | Common Stock | SSaleDisposed | −35,363 | $12.77 | −$451,585.51 | 1,548,499 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.